Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.57 |
| ▸ | CTSS | P25774 | 7/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989541 | 1.00 | CTSK (0.57) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL7534074 | 1.00 | CTSK (0.57) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL2400972 | 0.88 | CTSK (0.56) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL13446080 | 0.88 | CTSK (0.56) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL1519855 | 0.87 | PPARG (0.51) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL1519854 | 0.87 | PPARG (0.51) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL1519981 | 0.87 | PPARG (0.51) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL31341263 | 0.87 | CTSK (0.51) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL762688 | 0.86 | CTSK (0.57) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL12029033 | 0.86 | CTSK (0.51) | CTSKCTSSATMCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-7553969-B1 | Substituted phenethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553969-B1 | Substituted phenethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-6974869-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-5670497-A | RETROVIRAL PROTEASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5643878-A | TREATMENT OF RETROVIRAL DISEASES LIKE AIDS | CIBA-GEIGY CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | disclosed |
| EP-0708760-A1 | CYCLIC HYDRAZINE COMPOUNDS | Novartis AG (CH) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002582-A1 | CYCLIC HYDRAZINE COMPOUNDS | CIBA-GEIGY AG (CH) | 1995-01-26 | — | — | WO | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0532466-A2 | Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CTSK 174/4885CTSS 210/4885ATM 2171/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | CTSK 307/4885CTSS 199/4885ATM 1783/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CTSK 174/4885CTSS 210/4885ATM 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.